Hochschulschrift
Contribution of cyclin G2 to the cell cycle inhibitory effects of cancer therapeutics
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Bielefeld, Universität Bielefeld, Diss., 2012
- Classification
-
Biowissenschaften, Biologie
- Event
-
Veröffentlichung
- (where)
-
Bielefeld
- (who)
-
Universitätsbibliothek Bielefeld
- (when)
-
2012
- Creator
- URN
-
urn:nbn:de:hbz:361-26718308
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Zimmermann, Maike
- Universitätsbibliothek Bielefeld
Time of origin
- 2012
Other Objects (12)
Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
Cyclin G2 in macrophages triggers CTL-mediated antitumor immunity and antiangiogenesis via interferon-gamma
Cyclin F‐dependent degradation of E2F7 is critical for DNA repair and G2‐phase progression
Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk
Cyclin G2 suppresses Wnt/β-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1
G2
Copan, Altar G2 (CPN: Alt. G2)
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
Transplantation therapeutics
Arithmetical therapeutics
Antibody therapeutics
Advanced therapeutics
Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
Cyclin G2 in macrophages triggers CTL-mediated antitumor immunity and antiangiogenesis via interferon-gamma
Cyclin F‐dependent degradation of E2F7 is critical for DNA repair and G2‐phase progression
Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk
Cyclin G2 suppresses Wnt/β-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1
G2
Copan, Altar G2 (CPN: Alt. G2)
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
Transplantation therapeutics
Arithmetical therapeutics
Antibody therapeutics
Advanced therapeutics
Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
Cyclin G2 in macrophages triggers CTL-mediated antitumor immunity and antiangiogenesis via interferon-gamma
Cyclin F‐dependent degradation of E2F7 is critical for DNA repair and G2‐phase progression
Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk
Cyclin G2 suppresses Wnt/β-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1
G2
Copan, Altar G2 (CPN: Alt. G2)
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
Transplantation therapeutics
Arithmetical therapeutics
Antibody therapeutics